Starling Oncology (STLNW) Inventory (2020 - 2026)

Starling Oncology (STLNW) has reported Inventory for 7 consecutive years, with $20.0 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Inventory rose 26.76% year-over-year to $20.0 million; the trailing twelve-month figure through Jun 2026 stood at $20.0 million (up 26.76% YoY), and the FY2025 full-year result was $16.9 million, up 68.09% from the prior year.
• Inventory declined to $20.0 million in Q2 2026 per STLNW's latest filing, from $24.3 million in the prior quarter.
• Across five years, Inventory topped out at $24.3 million in Q1 2026 and bottomed at $7.8 million in Q1 2022.
• Historically, Inventory has averaged $13.1 million across 5 years, with a median of $11.9 million in 2023.
• The sharpest annual moves came in 2024 and 2026: Inventory decreased 26.6% in 2024, then surged 97.35% in 2026.
• Over 5 years, Inventory stood at $9.3 million in 2022, then surged by 47.69% to $13.7 million in 2023, then decreased by 26.6% to $10.0 million in 2024, then surged by 68.09% to $16.9 million in 2025, then gained by 18.58% to $20.0 million in 2026.
• According to Business Quant data, Inventory over the past three periods registered $20.0 million, $24.3 million, and $16.9 million for Q2 2026, Q1 2026, and Q4 2025 respectively.